Physician profile
Mohammed Muneeruddin
NPI 1649242488
$4,668.43
in general payments reported to CMS, 2019-2025
21 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.23 · 2020: $18.49 · 2021: $15.06 · 2022: $755 · 2023: $1,026 · 2024: $1,722 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,602 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,601.60 |
| Education | $202.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $623.60 | 2022-2025 | Verquvo, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $616.85 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $440.88 | 2024-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $428.14 | 2022-2025 | Farxiga, Lokelma, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $415.33 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.74 | 2019-2025 | Jardiance |
| Pfizer INC. | $245.11 | 2022-2025 | |
| Esperion Therapeutics, INC. | $239.87 | 2023-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $198.05 | 2022-2024 | Xarelto |
| Novo Nordisk INC | $184.08 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $183.77 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $148.05 | 2022-2023 | Mitraclip |
| Lexicon Pharmaceuticals, INC. | $124.56 | 2023-2024 | Inpefa |
| Glaxosmithkline, LLC. | $122.69 | 2024 | Arexvy |
| Abbvie INC. | $98.51 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $76.80 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $75.50 | 2022-2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $64.69 | 2023 | |
| Exact Sciences Corporation | $48.57 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $24.53 | 2022 | |
| Bridgebio Pharma, INC. | $19.11 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Muneeruddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.